High Blood Pressure: A First-of-Its-Kind Ranking of the Best-Tolerated Treatments Based on a Large-Scale Study

The Burden of Hypertension and the Challenge of Side Effects

According to a World Health Organization (WHO) report published in 2024, approximately 1.4 billion people worldwide are currently living with high blood pressure. Despite this significant figure, the proportion of patients who are able to manage this condition remains low. In fact, just over one in five people receives effective treatment, whether through medication or targeted lifestyle changes.

The fear of developing adverse effects is a major obstacle in the course of care. This apprehension often discourages people who have been diagnosed from starting treatment, accepting an increase in prescribed dosages, or adhering to long-term therapy consistently.

To better understand this phenomenon of treatment discontinuation, a large-scale analysis—the findings of which are detailed in a recent study published in the journal JAMA—examined the issue. The objective of this research was to identify which medications, or combinations of drugs, had the highest rates of side effects, and which were found to be the easiest for patients to tolerate.

Understanding the Mechanisms of Action of Treatments

High blood pressure is characterized by excessive pressure exerted by blood flow against the walls of the arteries. This phenomenon is often caused by a gradual narrowing of these small-diameter blood vessels, which alters the body’s overall vascular resistance.

This additional pressure forces the heart muscle to work harder than normal to pump blood. Over time, this process silently damages blood vessels and vital organs, making strict management through lifestyle changes and appropriate medication essential.

The three most commonly prescribed classes of medications work through distinct physiological mechanisms to lower blood pressure. Angiotensin II receptor antagonists (ARBs) block a hormone responsible for causing blood vessels to constrict, thereby allowing them to relax. Beta-blockers reduce heart rate to lower wall pressure, while calcium channel blockers prevent calcium from entering the cells of the heart and blood vessels, promoting their relaxation.

The Extent of Treatment Discontinuation and Its Causes

Despite the inherent severity of this cardiovascular condition and the progress made in developing antihypertensive therapies, the rate of treatment discontinuation remains very high. Statistics show that 30 to 80% of individuals receiving a new prescription stop taking their medication within the first year of treatment.

The majority of patients who discontinue their treatment regimen or who are reluctant to begin it at the time of diagnosis cite the inconvenience of taking daily pills. Poor tolerance of certain antihypertensive medications frequently results in chronic headaches, persistent fatigue, or uncomfortable swelling of the ankles.

It is important to note that the scientific community lacked recent data summarizing this issue. Over the past two decades, no comprehensive comparison had been conducted to rigorously evaluate individuals’ overall tolerance of various monotherapies and drug combinations intended to stabilize blood pressure.

Study Methodology: Network Meta-Analysis

To fill this gap in the literature, the researchers meticulously examined data from 159,362 participants. This information was extracted from 716 randomized, double-blind clinical trials, with follow-up periods ranging from four to twenty-six weeks of continuous observation.

The research team employed the complex technique of network meta-analysis. This sophisticated statistical method allows for the simultaneous comparison of multiple treatments, even when these specific drugs have never been directly compared within the same clinical trial. The primary objective was to quantify the frequency with which patients completely discontinued their medication due to side effects that had become intolerable.

During this process, the experts focused on four specific symptoms that frequently lead to discontinuation of treatment: headaches, dizziness, swelling, and coughing. All the collected data was then analyzed using a modeling tool called SUCRA (Surface Under the Cumulative Ranking curve), which enabled the creation of a detailed ranking table of tolerability, the prevalence of side effects, and the discontinuation rate for each treatment.

Clinical Results: The Best-Tolerated Combinations

The final analysis of this ranking revealed that angiotensin II receptor blockers had the lowest treatment discontinuation rates in the study, with even fewer discontinuations than those observed with a placebo. In terms of combination therapy, the combination of an angiotensin II receptor antagonist with a calcium channel blocker emerged as the best-tolerated option. Overall, angiotensin II receptor antagonists were included in four of the five treatment options deemed best tolerated by the panel.

Conversely, the use of calcium channel blockers alone was found to be significantly more likely to cause adverse effects, leading to a higher rate of treatment discontinuation. Treatment regimens including calcium channel blockers or combinations such as a beta-blocker paired with a diuretic (a substance that increases urine production) significantly increased the likelihood of premature discontinuation of treatment. Specifically regarding headaches, most of the treatments studied were associated with fewer headaches than placebo, with the notable exception of calcium channel blockers, which induce cerebral vasodilation known to trigger this symptom.

The study authors emphasize that further long-term research involving diverse populations is still needed to validate these findings. Ultimately, these data will enable healthcare professionals to optimize their prescribing practices by prioritizing medications capable of sustainably improving patient adherence to treatment. For any medical questions, consult a qualified healthcare professional.

Source: medicalxpress.com

High Blood Pressure: A First-of-Its-Kind Ranking of the Best-Tolerated Treatments Based on a Large-Scale Study